| Autor: |
Boente, M. Bastos, Sánchez, M. Alcoceba, Bailón, A. Navarro, Herrera, A. Medina, Álvarez, M. García, Sarasquete, M. E. Alonso, Santos, C. Chillón, Echevarría, A. Balanzategui, Gómez, A. Antón, Niño, J., Loizaga, I. de la Torre, Bedera, N. H. Vidaña, Sánchez, R. Maldonado, Ruano, M. Hernández, Sánchez, S. M. Lucas, Villares, M. I. Sánchez, González, A. I. Sánchez, González de la Calle, V., Díaz, M. González, Sánchez, C. Jiménez |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p748-748, 1p |
| Abstrakt: |
The MIPI53 model showed a better fit than the MIPI regarding PFS (AIC 240.9 vs. 245.9) and OS (AIC 120.25 vs 135.85). These results allowed the construction of a new prognostic model, MIPI53, which was able to separate the patients into 3 groups with different PFS (78% vs. 48% vs. 13% at 5 years, p < 0.001) and OS (100% vs. 85% vs. 27% at 5 years; p < 0.0001). The Mantle Cell Lymphoma International Prognostic Index (MIPI) allows risk stratification of patients based on clinical variables and is widely used to establish the prognosis of these patients. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text